However, early phase clinical trials using this pooled product in pediatric B-ALL demonstrated imbalanced CD19- and CD22-CAR T persistence, leading to antigen-negative relapse (73, 74). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.